Marrow-ablative treatment and autologous stem cell transplantation in follicular NHL

被引：8

作者：

Bachy, Emmanuel ^{[1
,2
]}

Salles, Gilles ^{[1
,2
,3
]}

机构：

[1] Hosp Civils Lyon, F-69495 Pierre Benite, France

[2] Univ Lyon 1, F-69495 Pierre Benite, France

[3] CNRS, UMR 5239, Lyon, France

来源：

BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY | 2011年 / 24卷 / 02期

关键词：

follicular lymphoma; autologous stem cell transplantation; rituximab; late toxicity; conditioning regimen; HIGH-DOSE THERAPY; NON-HODGKINS-LYMPHOMA; IBRITUMOMAB TIUXETAN RADIOIMMUNOTHERAPY; ACUTE MYELOGENOUS LEUKEMIA; TERM-FOLLOW-UP; SECONDARY MYELODYSPLASTIC SYNDROME; PROGRESSION-FREE SURVIVAL; ACUTE MYELOID-LEUKEMIA; REFRACTORY LOW-GRADE; BONE-MARROW;

D O I：

10.1016/j.beha.2011.03.001

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

High-dose therapy followed by autologous stem cell transplantation is widely accepted as salvage therapy for patients with relapsed aggressive lymphoma. In the pre-rituximab era, autologous stem cell transplantation had also been increasingly applied as a consolidation treatment for patients with indolent lymphoma in second or subsequent remission whereas controversies have emerged concerning its role in first line therapy from several randomized trials. Broad development and amazing efficacy of monoclonal antibody-based combination therapies for de novo or relapsing follicular lymphoma patients render previous conclusions outdated and underline the critical need for further phase III trials. This review focuses on available data from pre-rituximab and rituximab eras to help clarifying the precise role and timing of autologous stem cell transplantation among the current armamentarium for follicular lymphoma treatment. (C) 2011 Elsevier Ltd. All rights reserved.

引用

页码：257 / 270

页数：14

共 70 条

[21] IMMUNOLOGICAL PURGING OF MARROW ASSESSED BY PCR BEFORE AUTOLOGOUS BONE-MARROW TRANSPLANTATION FOR B-CELL LYMPHOMA [J].

GRIBBEN, JG ;

FREEDMAN, AS ;

NEUBERG, D ;

ROY, DC ;

BLAKE, KW ;

WOO, SD ;

GROSSBARD, ML ;

RABINOWE, SN ;

CORAL, F ;

FREEMAN, GJ ;

RITZ, J ;

NADLER, LM .

NEW ENGLAND JOURNAL OF MEDICINE, 1991, 325 (22) :1525-1533

[22] High-dose therapy followed by autologous purged stem cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by the GOELAMS with final results after a median follow-up of 9 years [J].

Gyan, Emmanuel ;

Foussard, Charles ;

Bertrand, Philippe ;

Michenet, Patrick ;

Le Gouill, Steven ;

Berthou, Christian ;

Maisonneuve, Herve ;

Delwail, Vincent ;

Gressin, Remi ;

Quittet, Philippe ;

Vilque, Jean-Pierre ;

Desablens, Bernard ;

Jaubert, Jerome ;

Ramee, Jean-Francois ;

Arakelyan, Nina ;

Thyss, Antoine ;

Molucon-Chabrot, Cecile ;

Delepine, Roselyne ;

Milpied, Noel ;

Colombat, Philippe ;

Deconinck, Eric .

BLOOD, 2009, 113 (05) :995-1001

[23] Rituximab purging and maintenance combined with auto-SCT: long-term molecular remissions and prolonged hypogammaglobulinemia in relapsed follicular lymphoma [J].

Hicks, L. K. ;

Woods, A. ;

Buckstein, R. ;

Mangel, J. ;

Pennell, N. ;

Zhang, L. ;

Imrie, K. ;

Spaner, D. ;

Cheung, M. C. ;

Boudreau, A. ;

Reis, M. ;

Crump, M. ;

Berinstein, N. L. .

BONE MARROW TRANSPLANTATION, 2009, 43 (09) :701-708

[24] Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone:: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group [J].

Hiddemann, W ;

Kneba, M ;

Dreyling, M ;

Schmitz, N ;

Lengfelder, E ;

Schmits, R ;

Reiser, M ;

Metzner, B ;

Harder, H ;

Hegewisch-Becker, S ;

Fischer, T ;

Kropff, M ;

Reis, HE ;

Freund, M ;

Wörmann, B ;

Fuchs, R ;

Planker, M ;

Schimke, J ;

Eimermacher, H ;

Trümper, L ;

Aldaoud, A ;

Parwaresch, R ;

Unterhalt, M .

BLOOD, 2005, 106 (12) :3725-3732

[25] High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: Analysis of the Stanford University results and prognostic indices [J].

Horning, SJ ;

Chao, NJ ;

Negrin, RS ;

Hoppe, RT ;

Long, GD ;

Hu, WW ;

Wong, RM ;

Brown, BW ;

Blume, KG .

BLOOD, 1997, 89 (03) :801-813

[26]

HORNING SJ, 1993, SEMIN ONCOL, V20, P75

[27] Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin's lymphoma [J].

Hosing, C ;

Munsell, M ;

Yazji, S ;

Andersson, B ;

Couriel, D ;

de Lima, M ;

Donato, M ;

Gajewski, J ;

Giralt, S ;

Körbling, M ;

Martin, T ;

Ueno, NT ;

Champlin, RE ;

Khouri, IF .

ANNALS OF ONCOLOGY, 2002, 13 (03) :450-459

[28] Secondary myelodysplastic syndrome and acute myelogenous leukemia are significant complications following autologous stem cell transplantation for lymphoma [J].

Howe, R ;

Micallef, INM ;

Inwards, DJ ;

Ansell, SM ;

Dewald, GW ;

Dispenzieri, A ;

Gastineau, DA ;

Gertz, MA ;

Geyer, SM ;

Hanson, CA ;

Lacy, MQ ;

Tefferi, A ;

Litzow, MR .

BONE MARROW TRANSPLANTATION, 2003, 32 (03) :317-324

[29] Intensive therapies in follicular non-Hodgkin lymphomas [J].

Hunault-Berger, M ;

Ifrah, N ;

Solal-Celigny, P .

BLOOD, 2002, 100 (04) :1141-1152

[30] 131I-tositumomab therapy as initial treatment for follicular lymphoma [J].

Kaminski, MS ;

Tuck, M ;

Estes, J ;

Kolstad, A ;

Ross, CW ;

Zasadny, K ;

Regan, D ;

Kison, P ;

Fisher, S ;

Kroll, S ;

Wahl, RL .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (05) :441-449

← 1 2 3 4 5 6 7 →